Skip to content
Home/Companies/Biotech/Glycovaxin

Glycovaxin

Biotech·France·Exited 2015·Held 6yr
Entry
2009
Hold
6yr
Exit
2015

Who owns Glycovaxin?

Glycovaxin is a French Biotech company, now owned by GSK, which acquired it in 2015 from Andera Partners.

Hand-verified · updated 2026-04-21

Open JSON · CC-BY
Andera Partners
Investor
Andera Partners
BioDiscovery 3 · 2009 · VC

Key facts

HQFrance
SectorBiotech
Exit Type
Trade Sale
Buyer
GSK
Exit Year
2015

More from BioDiscovery 3

Other portfolio companies in the same fund.

Cellnovo
Exited 2015
MedTechFrance· 2011
GenKyoTex
Exited 2014
BiotechFrance· 2011
Sapiens
Sapiens
Exited 2013
SaaSFrance· 2011
to Medtronic
Covagen
Exited 2014
BiotechFrance· 2010
to Johnson & Johnson
Parvulus Medical
Exited
MedTechFrance· 2010
Poxel
Poxel
Active
BiotechFrance· 2010

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Glycovaxin?

Glycovaxin is now owned by GSK, which acquired it in 2015 from Andera Partners.

When did GSK acquire Glycovaxin?

GSK acquired Glycovaxin in 2015, buying from Andera Partners.

Who did Glycovaxin sell to?

Andera Partners sold Glycovaxin to GSK in 2015 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue